| 0.3479 0.002 (0.64%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.4 |
1-year : | 0.47 |
| Resists | First : | 0.34 |
Second : | 0.4 |
| Pivot price | 0.31 |
|||
| Supports | First : | 0.23 |
Second : | 0.16 |
| MAs | MA(5) : | 0.31 |
MA(20) : | 0.32 |
| MA(100) : | 0.29 |
MA(250) : | 0.28 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 91.6 |
D(3) : | 82.7 |
| RSI | RSI(14): 63.1 |
|||
| 52-week | High : | 0.39 | Low : | 0.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ASXC ] has closed below upper band by 6.0%. Bollinger Bands are 21.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.35 - 0.35 | 0.35 - 0.35 |
| Low: | 0.34 - 0.34 | 0.34 - 0.35 |
| Close: | 0.35 - 0.35 | 0.35 - 0.35 |
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Thu, 22 Aug 2024
Asensus Surgical Announces Closing of Acquisition by KARL STORZ - GlobeNewswire
Thu, 22 Aug 2024
Asensus Surgical Announces Closing of Acquisition by KARL STORZ - Stock Titan
Wed, 14 Aug 2024
Asensus Surgical will file bankruptcy if Karl Storz merger fails - MassDevice
Wed, 24 Jul 2024
Asensus Surgical Announces The Rocky Mountain Hospital for Children in Denver, Colorado to Initiate Senhance Surgery Program - Quantisnow
Tue, 23 Jul 2024
Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology - GlobeNewswire
Mon, 17 Jun 2024
Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 264 (M) |
| Held by Insiders | 2.597e+008 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 18,600 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.613e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 826.7 % |
| Return on Equity (ttm) | -50.1 % |
| Qtrly Rev. Growth | 5.61e+006 % |
| Gross Profit (p.s.) | -37.83 |
| Sales Per Share | -64.95 |
| EBITDA (p.s.) | -2.49342e+006 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 2.93 |
| Dividend | 0 |
| Forward Dividend | 2.013e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|